BRPI0418273A - imunógenos alvejados - Google Patents

imunógenos alvejados

Info

Publication number
BRPI0418273A
BRPI0418273A BRPI0418273-1A BRPI0418273A BRPI0418273A BR PI0418273 A BRPI0418273 A BR PI0418273A BR PI0418273 A BRPI0418273 A BR PI0418273A BR PI0418273 A BRPI0418273 A BR PI0418273A
Authority
BR
Brazil
Prior art keywords
immunogens
immunogen
reagents
targeted
enhanced
Prior art date
Application number
BRPI0418273-1A
Other languages
English (en)
Inventor
A Robert Uger
Danielle Salha
Scott Gallinchan
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of BRPI0418273A publication Critical patent/BRPI0418273A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Imunógenos alvejados A presente invenção refere-se a reagentes e métodos para produzir e utilizar imunógenos alvo. Em modalidades preferidas, um imunógeno é conjugado a uma seqüência de aminoácido que alveja o imunógeno para a trilha de apresentação. Usando-se os reagentes e métodos fornecidos aqui, protocolos de imunização podem ser realçados resultando em imunidade aumentada do hospedeiro.
BRPI0418273-1A 2003-12-31 2004-12-30 imunógenos alvejados BRPI0418273A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53372803P 2003-12-31 2003-12-31
PCT/US2004/044023 WO2005066203A2 (en) 2003-12-31 2004-12-30 Targeted immunogens

Publications (1)

Publication Number Publication Date
BRPI0418273A true BRPI0418273A (pt) 2007-05-02

Family

ID=34748948

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418273-1A BRPI0418273A (pt) 2003-12-31 2004-12-30 imunógenos alvejados

Country Status (12)

Country Link
US (1) US20060002946A1 (pt)
EP (1) EP1699492A2 (pt)
JP (1) JP2007536911A (pt)
KR (1) KR20060129353A (pt)
CN (1) CN1921889A (pt)
AU (1) AU2004312548A1 (pt)
BR (1) BRPI0418273A (pt)
CA (1) CA2552251A1 (pt)
IL (1) IL176603A0 (pt)
MX (1) MXPA06007574A (pt)
WO (1) WO2005066203A2 (pt)
ZA (1) ZA200605304B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
CN110038135B (zh) 2011-03-17 2021-03-05 伯明翰大学 重新定向的免疫治疗
WO2016131856A1 (en) * 2015-02-18 2016-08-25 F. Hoffmann-La Roche Ag Immunoconjugates for specific induction of t cell cytotoxicity against a target cell
WO2016179584A1 (en) * 2015-05-07 2016-11-10 University Of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE391791T1 (de) * 2000-08-25 2008-04-15 Aventis Pharma Inc Membran penetrierende peptide und deren anwendungen
EP1496927A4 (en) * 2002-01-29 2007-09-12 Aventis Pasteur IMMUNOGENES TARGETS

Also Published As

Publication number Publication date
AU2004312548A1 (en) 2005-07-21
MXPA06007574A (es) 2007-04-17
KR20060129353A (ko) 2006-12-15
CN1921889A (zh) 2007-02-28
CA2552251A1 (en) 2005-07-21
WO2005066203A3 (en) 2005-09-01
JP2007536911A (ja) 2007-12-20
EP1699492A2 (en) 2006-09-13
WO2005066203A2 (en) 2005-07-21
IL176603A0 (en) 2006-10-31
ZA200605304B (en) 2007-12-27
US20060002946A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
CY1122117T1 (el) Ενεργοποιηση μιας ανοσοαποκρισης
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
BR122018016045B8 (pt) proteína variante otimizada
MX2010008633A (es) Ruptura de tolerancia inmunologica con un aminoacido no natural geneticamente codificado.
BRPI0509819A (pt) integração de marca d' água
BRPI0817299A8 (pt) vacinas e componentes de vacina para inibição de células microbianas
AU2002242016A1 (en) Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
PT1117421E (pt) Novos metodos para vacinacao terapeutica
BRPI0416744A (pt) sistemas de expressão de proteìna aperfeiçoados
AU2003217285A1 (en) Expandable fastener with compressive grips
NO20051469L (no) Immunstimulerende nukleinsyrer.
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
BRPI0513237A (pt) hidrolisados de proteìna para diminuição de pressão sanguìnea
PT1487282E (pt) Processo para a preparacao de extractos de tomate com um elevado conteudo de licopeno
BRPI0412245A (pt) anticorpos de rg1 e usos destes
BR112013030124A2 (pt) conjunto direcionador ajustável
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
BRPI0418273A (pt) imunógenos alvejados
BR0312856A (pt) Aditivo de solo e método para produção do mesmo
WO2003064609A3 (en) Targeted immunogens
BRPI0411815A (pt) vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas
BRPI0510385A (pt) vetores virais polivalentes e um sistema para produção destes
BR9915330A (pt) Método para imunizar uma ave contra uma doença

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: C07K 14/47 (2006.01), A61K 39/00 (2006.01)